Abstract

Background: Despite the National Plan for the Elimination of Measles and congenital Rubella (NPEMcR), in 2017, a measles outbreak occurred in Italy, due to sub-optimal vaccination coverage (<95%) for many years. Since that year, the anti-measles vaccination became compulsory in minors (0–16 years) for school attendance. The aim of our study was to assess the immunity/susceptibility against measles in a representative sample of pediatric and adolescent (1–18 years) residents of the province of Florence (Tuscany, Italy), and to compare these results with two previous surveys (2003 and 2005–2006). Methods: The enzyme-linked immunosorbent assay (ELISA) was applied for a qualitative measurement of anti-measles antibodies on 165 sera. The anamnestic and vaccination status was also collected. Results: No measles notification was reported. The overall seropositivity was 88.5%; mostly in the 5–9 years old subjects (97.9%). Among the 152 vaccinated, 92.1% were positive. The seropositivity persisted after many years since the last dose of vaccine and tended to be more long-lasting in those who had received two or three doses. The susceptibility towards measles decreased over time, reaching a lower value in the current survey (8.5%) than in 2003 (30.8%) and in 2005–2006 (25.5%). Conclusions: This study confirmed the anti-measles vaccination campaign success, which allowed for the increase in vaccination coverage and immunity levels against measles in the Florentine pediatric and adolescent population following the NPEMcR implementation.

Highlights

  • Measles is a highly contagious viral infectious disease known globally

  • Our study assessed the measles seroprevalence in a sample of sera representative of the pediatric and adolescent population residing in the province of Florence

  • 88.5%, and highest immunity level were found in the 5–9-year old subjects (97.9%)

Read more

Summary

Introduction

Measles is a highly contagious viral infectious disease known globally. Despite the availability of an effective and safe vaccine since 1960s, the mortality amongst young children (1–3 years old) remainsVaccines 2020, 8, 512; doi:10.3390/vaccines8030512 www.mdpi.com/journal/vaccinesVaccines 2020, 8, 512 high worldwide [1]. Despite the availability of an effective and safe vaccine since 1960s, the mortality amongst young children (1–3 years old) remains. The measles virus (MV) belongs to the genus Morbillivirus of the family Paramyxoviridae. The first mainly occur in the winter because of an intensification of social risk factors (i.e., crowded enclosed places); the second, on the other hand, is mainly due to an accumulation of susceptible subjects who have never been vaccinated or previously contracted the disease [5]. Despite the National Plan for the Elimination of Measles and congenital Rubella (NPEMcR), in 2017, a measles outbreak occurred in Italy, due to sub-optimal vaccination coverage (

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call